University of Vermont

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Vermont sits in the top decile of US sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count).

162 total trials 15 currently recruiting 132 completed early-phase tilt top decile by trial count

University of Vermont: 162 sponsored US clinical trials, 15 recruiting.

University of Vermont sponsors 162 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 132 completed. 5 of these trials are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid-Related Disorders, with 4 trials.

Top-decile sponsor footprint

University of Vermont ranks in the top decile of sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 74/100

132 of 141 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

162 total, page 4 of 4

COMPLETED

Outpatient Prescription Errors: Detection, Analysis, and Impact on Safety

NCT00256568
COMPLETED NA

Effects and Mechanisms of Specific Trunk Exercises in Low Back Pain

NCT01611792
COMPLETED NA

Weight Loss on the Web: A Pilot Study Comparing a Commercial Website to a Structured Behavioral Intervention

NCT00263172
COMPLETED Phase 3

Methods of Weight Loss in Overweight Coronary Patients

NCT00628277
COMPLETED Phase 2

Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22

NCT00000240
COMPLETED Phase 2

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

NCT00005579
COMPLETED Phase 2

Buprenorphine Detox With Two Types of Treatment. BBD II - 11

NCT00000229
COMPLETED Phase 2

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

NCT00000230
COMPLETED Phase 2

Alternate-Day Buprenorphine Administration. Phase VIII - 9

NCT00000227
COMPLETED Phase 2

Alternate Day Buprenorphine Administration, Phase IX - 14

NCT00000232
COMPLETED Phase 1

Buprenorphine Dose Alteration Study - 1

NCT00000219
COMPLETED Phase 2

Alternate Day Buprenorphine Administration, Phase XI - 16

NCT00000234
← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 26
Phase 3 2
Phase 4 3

Therapeutic Areas

Opioid-Related Disorders 4
Tobacco Use Disorder 3
Neoplasms 2
Electronic Cigarette Use 2
Overweight 2
Obesity 2
Cancer Thrombosis 1
Asthma, Exercise Induced 1
Celiac Sprue 1
Drug-Induced Movement Disorder 1

What is open in the University of Vermont pipeline

15 recruiting of 162 indexed (9% open); 132 completed (81%).

Phase mix: 5 late (III/IV) vs 49 early (I/II) (early-phase heavy).

Top condition: Opioid-Related Disorders (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Vermont: open-pipeline peers nationwide

Peers matched on 162 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

University of Vermont sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 4%6%8%10%12%14% Total trials Recruiting share University of VermontAlexion PharmaceuticalsTemple UniversityTufts UniversityWayne State UniversityShionogiUniversity of KentuckyEli Lilly and CompanyLahey Clinic
University of Vermont sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Vermont sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 162 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Vermont page

162 registered trials is a research-attention snapshot, not an endorsement of University of Vermont or any single study.

  • 15 of University of Vermont's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid-Related Disorders is the condition University of Vermont studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid-Related Disorders trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Vermont pipeline card: 162 registered trials from official public datasets.Report a data error.